drugset / Trial / NCT02571569
A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors
Non-randomizedParallel-groupOpen-labelBasic science
Summary
Investigate the safety, tolerability and pharmacokinetics of BAY1093884 after Intravenous (IV) and subcutaneous (SC) administration of increasing single doses and SC administration of multiple doses.
Timeline
- Start
- 2015-10-28
- Primary completion
- 2018-07-09
- Completion
- 2018-10-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAY1093884 | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | BAY1093884 | Monoclonal antibody | 150 mg | Intravenous |